
Opinion|Videos|August 13, 2024
Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data
Experts give an overview of the ASCO 2024 data.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
The phase 2
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
TRT myths, metabolic risk, and the role of the urologist
3
How sex influences the bladder cancer tumor microenvironment
4
John Michael DiBianco, MD, highlights trial of stent omission after ureteroscopy
5



















